Composition
- Active ingredients
- RIVASTIGMINE TARTRATE EQ 2MG BASE/ML
Strengths and forms
The FDA lists each strength of a product separately; these pages share one label.
- RIVASTIGMINE TARTRATE EQ 4.5MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · CapsuleNDA020823-005 · Discontinued
- RIVASTIGMINE TARTRATE EQ 1.5MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · CapsuleNDA020823-003 · Discontinued
- RIVASTIGMINE TARTRATE EQ 6MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · CapsuleNDA020823-006 · Discontinued
- RIVASTIGMINE TARTRATE EQ 3MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · CapsuleNDA020823-004 · Discontinued
- RIVASTIGMINE TARTRATE EQ 2MG BASE/ML · SolutionThis page
Official product information
Drugs@FDA lists the approved labels, letters and reviews for application NDA021025.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Brand name
- Exelon
- Active substance
- rivastigmine tartrate
- Route
- Oral
- Dosage form
- Solution
- Applicant
- Novartis
- Status
- Discontinued
- FDA approval
- 21 Apr 2000
- Application
- NDA021025-001